Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 3:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 5,570 matching trials from the live ClinicalTrials.gov search.
Conditions
HIV Infections
Interventions
Aluminum hydroxide, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
4
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 1 more
Conditions
Carcinoma
Interventions
Sorafenib 100 mg (50-mg tablet), Sorafenib 200 mg (50-mg tablet), Sorafenib 400 mg (50-mg tablet), Sorafenib 400 mg (200-mg tablet), Sorafenib 400 mg (Expansion)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee • Madison, Wisconsin
Conditions
Heart Failure, Systolic, Frailty
Interventions
sacubitril/valsartan, Angiotensin II Receptor Blockers
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
40,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Tumors
Interventions
BSI-201 (iniparib), irinotecan
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
New Haven, Connecticut • Houston, Texas • San Antonio, Texas
Completed Phase 3 Interventional Results available

Buprenorphine for Treatment Resistant Depression

NCT01407575
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Lung Cancer
Interventions
thalidomide, adjuvant therapy
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • Cleveland, Ohio
Conditions
Colorectal Carcinoma
Interventions
SU011248, Irinotecan, Cetuximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Kidney Cancer
Interventions
motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hepatitis C, Transplantation Disease Transmission
Interventions
Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Conditions
Advanced and/or Metastatic Sarcoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
Interventions
Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
Device · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
Interventions
Nivolumab, Autologous CD30.CAR-T, Fludarabine, Bendamustine
Drug
Lead sponsor
Tessa Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Chapel Hill, North Carolina + 1 more
Terminated Phase 2 Interventional Accepts healthy volunteers

Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™

NCT02221232
Conditions
Surgical Site Infection
Interventions
Chloraprep, ZuraPrep, ZuraPrep Vehicle
Drug
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Conditions
Parkinson's Disease
Interventions
IPX066, CLE
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Fresno, California • Sunnyvale, California • Miami, Florida + 9 more
Conditions
New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
Interventions
Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy
Drug · Procedure
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

NCT07007806
Conditions
Healthy Volunteer Study
Interventions
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cypress, California
Conditions
Pain
Interventions
ibuprofen, acetaminophen with codeine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
5 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Diego, California
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone, Pharmacist-administered buprenorphine/naloxone maintenance care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Durham, North Carolina • Raleigh, North Carolina
Conditions
Asthma
Interventions
Fluticasone Propionate, Fluticasone Propionate/Salmeterol, Placebo MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 59 more
Conditions
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
Interventions
Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab
Procedure · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Miami, Florida
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy, Biospecimen Collection, Enfortumab Vedotin, MR Urography, Nephroureterectomy, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Interventions
SM88 (Cohort 1), SM88 (Cohort 2)
Drug
Lead sponsor
Tyme, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Lawrence, New Jersey • Garden City, New York • The Bronx, New York + 1 more
Conditions
Treatment of Hepatitis C
Interventions
Ledipasvir/Sofosbuvir FDC
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California